Q3 2020 Sales Performance

Over the last two years we have made significant progress gsk July 2018 to July 2020 Over 40% of our POC studies have been positive . Enabling us to initiate 9 potentially registrational studies We delivered 17 positive pivotal studies We are on track for 14 approvals, including up to 5 NMEs in 2020 We focused the pipeline by removing 24 assets of marginal value and added 20 very promising assets 21 21

View entire presentation